Credit Suisse analyst Richard Law lowered the firm’s price target on Crispr Therapeutics to $65 from $78 and keeps a Neutral rating on the shares following quarterly results. The firm notes that submission for exa-cel’s BLA for rolling review is on track to complete by Q1 2023, and that the company plans to initiate clinical trials for its second-gen CAR-Ts including CTX131 in February after its IND clearance and CTX112 in the first half of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Crispr Therapeutics options imply 4.4% move in share price post-earnings
- Crispr Therapeutics options imply 4.9% move in share price post-earnings
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences
- Crispr Therapeutics price target lowered to $70 from $100 at JMP Securities
